Related Experiment Video

Updated: Jul 8, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery

Patricia A Howard1, Brian J Barnes

  • 1Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, Kansas City, KS 66160, USA. phoward@kumc.edu

The Annals of Pharmacotherapy
|January 17, 2008
PubMed

Insights

Statins show promise in preventing postoperative atrial fibrillation (POAF) after coronary artery bypass graft (CABG) surgery. Further research is needed to confirm their effectiveness as an adjunct therapy.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Postoperative atrial fibrillation (POAF) is a frequent complication after coronary artery bypass graft (CABG) surgery, associated with increased morbidity.
  • Current prevention strategies include beta-blockers and antiarrhythmic drugs, which carry inherent risks.

Purpose of the Study:

  • To review existing literature on the efficacy of statin therapy in preventing POAF following CABG surgery.
  • To assess the potential role of statins as an adjunct to established POAF prevention methods.

Main Methods:

  • A comprehensive literature search of MEDLINE (1950-October 2007) was conducted using relevant keywords.
  • Inclusion criteria encompassed all English-language studies evaluating statins for AF prevention in humans, supplemented by reference list reviews.

Main Results:

  • Evidence from non-surgical patients suggests statins reduce AF rates.
  • Observational studies in CABG patients indicate a potential benefit.
  • One randomized controlled trial demonstrated a significant reduction in POAF and hospital stay with preoperative atorvastatin.

Conclusions:

  • Current evidence for statins preventing POAF is encouraging but not definitive.
  • Statins may offer benefits through pleiotropic effects beyond cholesterol reduction.
  • Further investigation is warranted to establish statin efficacy, optimal use in risk-stratified patients, and impact on outcomes and costs.
Abstract

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...